4c5w: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
Line 3: Line 3:
<StructureSection load='4c5w' size='340' side='right'caption='[[4c5w]], [[Resolution|resolution]] 1.70&Aring;' scene=''>
<StructureSection load='4c5w' size='340' side='right'caption='[[4c5w]], [[Resolution|resolution]] 1.70&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[4c5w]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4C5W OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=4C5W FirstGlance]. <br>
<table><tr><td colspan='2'>[[4c5w]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4C5W OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4C5W FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=16D:HEXANE-1,6-DIAMINE'>16D</scene>, <scene name='pdbligand=NM3:ETHYL-DIMETHYL-(4-OXIDANYL-4-OXIDANYLIDENE-BUTYL)AZANIUM'>NM3</scene>, <scene name='pdbligand=OGA:N-OXALYLGLYCINE'>OGA</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=16D:HEXANE-1,6-DIAMINE'>16D</scene>, <scene name='pdbligand=NM3:ETHYL-DIMETHYL-(4-OXIDANYL-4-OXIDANYLIDENE-BUTYL)AZANIUM'>NM3</scene>, <scene name='pdbligand=OGA:N-OXALYLGLYCINE'>OGA</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4bg1|4bg1]], [[4bgk|4bgk]], [[4bgm|4bgm]], [[4bhf|4bhf]], [[4bhi|4bhi]]</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4c5w FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4c5w OCA], [https://pdbe.org/4c5w PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4c5w RCSB], [https://www.ebi.ac.uk/pdbsum/4c5w PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4c5w ProSAT]</span></td></tr>
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Gamma-butyrobetaine_dioxygenase Gamma-butyrobetaine dioxygenase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.14.11.1 1.14.11.1] </span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=4c5w FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4c5w OCA], [http://pdbe.org/4c5w PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4c5w RCSB], [http://www.ebi.ac.uk/pdbsum/4c5w PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4c5w ProSAT]</span></td></tr>
</table>
</table>
== Function ==
== Function ==
[[http://www.uniprot.org/uniprot/BODG_HUMAN BODG_HUMAN]] Catalyzes the formation of L-carnitine from gamma-butyrobetaine.  
[[https://www.uniprot.org/uniprot/BODG_HUMAN BODG_HUMAN]] Catalyzes the formation of L-carnitine from gamma-butyrobetaine.
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Gamma butyrobetaine hydroxylase (BBOX) catalyzes the conversion of gamma butyrobetaine (GBB) to L-carnitine, which is involved in the generation of metabolic energy from long chain fatty acids. BBOX inhibitor 3-(1,1,1-trimethylhydrazin-1-ium-2-yl)propanoate (mildronate), which is an approved, clinically used cardioprotective drug, is a relatively poor BBOX inhibitor and requires high daily doses. In this disclosure, we describe the design, synthesis and properties of 51 compounds, which include both GBB and mildronate analogues. We have discovered novel BBOX inhibitors with improved IC50 values; the best examples are in nanomolar range and about two orders of magnitude better when compared to mildronate. For 6 inhibitors, crystal structures in complex with BBOX have been solved to explain their activities and pave way for further inhibitor design.
 
Targeting carnitine biosynthesis: discovery of new inhibitors against gamma-butyrobetaine hydroxylase.,Tars K, Leitans J, Kazaks A, Zelencova D, Liepinsh E, Kuka J, Makrecka M, Lola D, Andrianovs V, Gustina D, Grinberga S, Liepinsh E, Kalvinsh I, Dambrova M, Loza E, Pugovics O J Med Chem. 2014 Feb 26. PMID:24571165<ref>PMID:24571165</ref>
 
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 4c5w" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Gamma-butyrobetaine dioxygenase]]
[[Category: Homo sapiens]]
[[Category: Human]]
[[Category: Large Structures]]
[[Category: Large Structures]]
[[Category: Kazaks, A]]
[[Category: Kazaks A]]
[[Category: Leitans, J]]
[[Category: Leitans J]]
[[Category: Tars, K]]
[[Category: Tars K]]
[[Category: Oxidoreductase]]
Retrieved from "https://proteopedia.org/4c5w"